A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of Inhaled HH-120 Aerosol in Healthy Volunteers
Latest Information Update: 28 Sep 2023
At a glance
- Drugs HH-120 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Huahui Health
- 22 Sep 2023 Status changed from recruiting to completed.
- 01 Sep 2022 Planned End Date changed from 1 May 2022 to 28 Sep 2022.
- 13 Dec 2021 Status changed from not yet recruiting to recruiting, according to a Huahui Health media release.